Compare WKHS & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKHS | AYTU |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 20.5M |
| IPO Year | N/A | N/A |
| Metric | WKHS | AYTU |
|---|---|---|
| Price | $6.54 | $2.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $21.00 | $9.33 |
| AVG Volume (30 Days) | ★ 529.0K | 47.6K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $10,620,296.00 | ★ $63,696,000.00 |
| Revenue This Year | $92.70 | N/A |
| Revenue Next Year | $34.00 | $47.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.73 | N/A |
| 52 Week Low | $6.30 | $0.95 |
| 52 Week High | $168.00 | $2.82 |
| Indicator | WKHS | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 81.87 | 62.26 |
| Support Level | $6.30 | $2.05 |
| Resistance Level | $11.80 | $2.30 |
| Average True Range (ATR) | 0.60 | 0.12 |
| MACD | 0.72 | 0.03 |
| Stochastic Oscillator | 52.51 | 87.63 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.